Global X Russell 2000 Covered Call ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Global X Russell 2000 Covered Call ETF RYLD
Morningstar’s Analysis RYLD
Will RYLD outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the RYLD management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of RYLD’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 99.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Global X Russell 2000 ETF | 102.51 | 1B | — |
Cash | 0.16 | 2M | Cash and Equivalents |
Warrant on Inhibrx Inc Ordinary Shares | 0.00 | 10,269 | — |
Warrant on Novartis AG Registered Shares | 0.00 | 10,157 | — |
Pulse Biosciences ([Wts/Rts]) 0% | 0.00 | 8,030 | — |
Canadian Dollar | 0.00 | 5,090 | Cash and Equivalents |
Cartesian Therapeutics ([Wts/Rts]) 0% | 0.00 | 0 | — |
Omniab | 0.00 | 0 | — |
Omniab | 0.00 | 0 | — |
Rut Us 06/18/26 C2800 | −2.67 | −36M | — |
United States